Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
Cephalalgia · 2023-01 · 43 (1)
DOI: 10.1177/03331024221128250 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 09.01.2023. Verfasst von Brad C Klein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Abington Neurological Associates, Ltd., Abington, PA, USA. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc..
Abstract (Originalsprache)
Background
Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of atogepant in participants who completed the phase 3 ADVANCE trial (NCT03777059).
Methods
This 40-week, open-label extension trial (NCT03939312) monitored safety in participants receiving oral atogepant 60 mg once daily, followed by a four-week safety follow-up period.
Results
Of the 685 participants taking at least one dose of atogepant, the treatment period was completed by 74.6% of participants with a mean (standard deviation) treatment duration of 233.6 (89.3) days. Treatment-emergent adverse events occurred in 62.5% of participants, with upper respiratory tract infection (5.5%), urinary tract infection (5.3%), nasopharyngitis (4.8%), sinusitis (3.6%), constipation (3.4%), and nausea (3.4%) occurring at ≥3%. Serious adverse events were observed in 3.4% of participants (none were treatment-related), and there were no deaths. Adverse events leading to discontinuation occurring at >0.1% were nausea (0.4%) and abdominal pain, vomiting, weight decrease, dizziness, and migraine (0.3% each).
Conclusion
These results are consistent with atogepant’s known safety profile and support long-term use of atogepant 60 mg once daily dosing as safe and well tolerated. ClinicalTrials.gov Registration Number: NCT03939312
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Abington Neurological Associates, Ltd., Abington, PA, USA.
- AbbVie Inc., Madison, NJ, USA.
- New England Institute for Neurology & Headache, Stamford, CT, USA.
- DENT Neurologic Institute, Amherst, NY, USA.
- Diamond Headache Clinic, Chicago, IL, USA.
- Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
ORCID-Profile: Laszlo Mechtler
Förderung
- AbbVie Inc.
Zitieren
APA
Klein, B. C., Miceli, R., Severt, L., McAllister, P., Mechtler, L., McVige, J., Diamond, M., Marmura, M. J., Guo, H., Finnegan, M., & Trugman, J. M. (2023). Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia, 43(1). https://doi.org/10.1177/03331024221128250
Vancouver
Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, et al. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia. 2023;43(1). doi:10.1177/03331024221128250
BibTeX
@article{Klein2023,
author = {Klein, Brad C and Miceli, Rosa and Severt, Lawrence and McAllister, Peter and Mechtler, Laszlo and McVige, Jennifer and Diamond, Merle and Marmura, Michael J and Guo, Hua and Finnegan, Michelle and Trugman, Joel M},
title = {Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial},
journal = {Cephalalgia},
year = {2023},
volume = {43},
number = {1},
doi = {10.1177/03331024221128250}
}
EUVIMED